B+
Bull case
30%
Probability
Target price
$10.50
+78.3% vs current
XERS
Xeris BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$7.80
+32.4% vs current
B-
Bear case
25%
Probability
Target price
$5.00
-15.1% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+68.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+81.1
Score
AI commentary
As of May 8, 2026, the freshest evidence is supportive but still early: the May 7 company release was strong on revenue growth, profitability, and guidance tightening, and same-day/AP-style earnings coverage was directionally positive. However, this is a T+1 follow-up on a low-coverage biopharma name, analyst revision data is still thin, social-context coverage was not provided, and immediate price-reaction evidence was limited in the checked packet, so the setup remains a cautious post-earnings monitoring view rather than a fully de-risked bullish rerating call.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQ1 2026 print improved the near-term earnings setupHigh impact
On May 7, 2026, Xeris reported Q1 total revenue of $83.1 million, net product revenue up 43% year over year, Recorlev revenue up 95% to $49.8 million, positive net income of $2.2 million, and adjusted EBITDA of $15.1 million. Management also tightened 2026 total revenue guidance to $380 million-$390 million from the prior wider range, which supports a constructive near-term read-through after the earnings release [#8-K-2026-05-07].
2026-09-30catalystXP-8121 Phase 3 initiation remains the main pipeline upside leverHigh impact
The May 7, 2026 earnings release again framed 2026 as a pivotal pipeline year, with anticipated Phase 3 initiation for XP-8121 later in 2026. Successful initiation would broaden the story beyond the marketed portfolio, while delay would reinforce the view that Xeris is still primarily a commercial-execution name [#8-K-2026-05-07].
2026-10-01catalystRecorlev momentum and commercial-team expansion need to hold through 2H 2026High impact
Management said Recorlev nearly doubled year over year on increased patient demand and that the commercial-team expansion was completed in the quarter, with benefits expected to become more evident in the second half of 2026. If that converts into sustained portfolio growth beyond one standout quarter, the commercial thesis strengthens materially; if growth narrows back toward a single-product story, enthusiasm likely fades [#8-K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology